This article explores the use of the precautionary principle in situations of intermingled uncertainty and risk. It analyses how the so-called uncertainty paradox works out by examining the Pfizer case. It reveals regulatory complexities that result from contradictions in precautionary thinking. In conclusion, a plea is made for embedment of uncertainty information, while stressing the need to rethink regulatory reform in the broader sense.

This content is only available as a PDF.
You do not currently have access to this content.